Literature DB >> 810520

A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates.

H B Levy, G Baer, S Baron, C E Buckler, C J Gibbs, M J Iadarola, W T London, J Rice.   

Abstract

A comlex of polyriboinosinic-polyribocytidylic acid (poly I-poly C) with poly-L-lysine and carboxymethylcellulose has been prepared. This complex is five to 10 times as resistant to hydrolysis by primate serum as the parent poly I-poly C. It has a thermal denaturation temperature about 40 C higher than that of poly I-poly C. The complex induces significant levels of serum interferon in monkeys and chimpanzees under conditions in which poly I-poly C itself induces no interferon.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 810520     DOI： 10.1093/infdis/132.4.434

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  85 in total

1.  An effective rabies treatment in exposed monkeys: a single dose of interferon inducer and vaccine.

Authors:  G M Baer; S A Moore; J H Shaddock; H B Levy
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

2.  Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.

Authors:  Mayuka Horikawa; Veronique Minard-Colin; Takashi Matsushita; Thomas F Tedder
Journal:  J Clin Invest       Date:  2011-10-24       Impact factor: 14.808

3.  Immunotoxicity of immunotherapeutic agents.

Authors:  A G Johnson; J Regal
Journal:  Springer Semin Immunopathol       Date:  1985

4.  Interferon induction with polyinosinic:polycytidylic acid in the newborn piglet.

Authors:  K G Loewen; J B Derbyshire
Journal:  Can J Vet Res       Date:  1986-04       Impact factor: 1.310

5.  Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates.

Authors:  Barbara J Flynn; Kathrin Kastenmüller; Ulrike Wille-Reece; Georgia D Tomaras; Munir Alam; Ross W Lindsay; Andres M Salazar; Beatriz Perdiguero; Carmen E Gomez; Ralf Wagner; Mariano Esteban; Chae G Park; Christine Trumpfheller; Tibor Keler; Giuseppe Pantaleo; Ralph M Steinman; Robert Seder
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-05       Impact factor: 11.205

6.  Production of human lymphoblastoid interferon by Namalva cells.

Authors:  K C Zoon; C E Buckler; P J Bridgen; D Gurari-Rotman
Journal:  J Clin Microbiol       Date:  1978-01       Impact factor: 5.948

Review 7.  Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Authors:  Melody Smith; Elena García-Martínez; Michael R Pitter; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

8.  Modified polyriboinosinic-polyribocytidylic acid, an immunological adjuvant.

Authors:  W E Houston; C L Crabbs; E L Stephen; H B Levy
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

9.  Comparative activities of selected combinations of acyclovir, vidarabine, arabinosyl hypoxanthine, interferon, and polyriboinosinic acid-polyribocytidylic acid complex against herpes simplex virus type 2 in tissue culture and intravaginally inoculated mice.

Authors:  L R Crane; D A Milne; J C Sunstrum; A M Lerner
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

Review 10.  Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant.

Authors:  Bo Jin; Tao Sun; Xiao-Hong Yu; Chao-Qun Liu; Ying-Xiang Yang; Ping Lu; Shan-Feng Fu; Hui-Bin Qiu; Anthony E T Yeo
Journal:  J Biomed Biotechnol       Date:  2010-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.